News by Subject Medicine & Health

Analysis of all the proteins of more than 500 cancers from five different tissue sites revealed novel molecular pathways to be considered for further study regarding their potential involvement in cancer.

A team led by researchers at Baylor College of Medicine and Harvard Medical School has unveiled a novel mechanism that helps explain how endocrine-resistant breast cancer acquires metastatic behavior, opening the possibility of new therapeutic strategies.

A new study reveals the mechanism that helps pancreatic cancer cells avoid starvation within dense tumors by hijacking a process that pulls nutrients in from their surroundings.

What if scientists could create more effective drugs to treat cancers and other diseases by better targeting specific sites on proteins in the body? That's the primary question researchers in the Purdue University laboratory of Carol Post, a distinguished professor in Purdue's College of Pharmacy, are trying to answer. They developed software called NmrLineGuru to move researchers closer to the answer.

Phase III results at NEJM and SABCS: Adding tucatinib to standard of care treatment nearly tripled one-year progression-free survival.

'New therapeutic approaches are desperately needed for MLL-r leukaemia,' said Professor Richard Lock, Head of the Blood Cancers Theme at Children's Cancer Institute, Australia.

Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.